Trial Protocol ID USOR 20412_J2G-MC-JZJX_LIBRETTO-432 *STAR*

Trial Description

A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432)

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com or call us at 877-664-7724

Disease Types

Sponsors

  • ELI LILLY
  • IQVIA

ClinicalTrials.gov NCT ID

  • NCT04819100